Brentie:

Beat me to it...

MNKD excerpt:

"Mannkind has a game-changer in the diabetes market with their version of insulin called AFREZZA. For the past ninety years, patients with insulin-dependent diabetes have been forced to painfully administer their daily insulin doses through injection. Mannkind is looking to change the insulin delivery game. AFREZZA is a novel, ultra rapid-acting mealtime insulin therapy in late stage clinical investigation for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA inhalation powder, pre-metered into single-use dose cartridges, and the light, discreet, and easy-to-use AFREZZA inhaler. Because of its unique pharmacokinetic profile, AFREZZA may be a promising new therapy for patients with Type 1 and Type 2 diabetes, as it controls post meal-time glucose levels with less weight gain and lower risk of hypoglycemia. With potential approval in 2014, Mannkind could revolutionize how diabetes is treated. The question now: Will Mannkind partner prior to the FDA's decision? One thing for certain is that pharmaceutical giants Lilly (LLY) and Novo Nordisk (NVO) are watching closely. Annual sales of AFREZZA could be upwards of 3 billion."